CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units (“RSUs”) to one newly hired
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development program designed to support registration and global regulatory authorizations for SGT-003 - - Solid received a positive opinion from the European
CHARLESTOWN, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,070 restricted stock units (“RSUs”) to one newly hired
- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing
- Orphan drug designation from the European Commission underscores Solid’s commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy - CHARLESTOWN, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.